Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Curcumin on Anthropometric Indices, Blood Pressure, Lipid Profiles, Fasting Blood Glucose, Liver Enzymes, Fibrosis, and Steatosis in Non-Alcoholic Fatty Livers Publisher



Safari Z1 ; Bagherniya M1, 2 ; Khoram Z3 ; Ebrahimi Varzaneh A3 ; Heidari Z4, 5 ; Sahebkar A6, 7, 8 ; Askari G1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nutrition and Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Isfahan Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. School of Medicine, The University of Western Australia, Perth, WA, Australia

Source: Frontiers in Nutrition Published:2023


Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease. Curcumin is a natural polyphenol that may be effective against liver steatosis and steatohepatitis. The present study aimed to evaluate the effects of phytosomal curcumin on lipid profile, fasting blood sugar, anthropometric indices, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty liver patients. Methods: The participants were randomized to the curcumin–phosphatidylserine phytosomal receiving group and the placebo receiving group and were followed up for 12 weeks. Data on anthropometric indices, lipid profile, blood glucose, blood pressure, liver enzymes, hepatic steatosis, and fibrosis were collected at the beginning and the end of the clinical trial. Results: Supplementation for 12 weeks with phytosomal curcumin significantly reduced fibrosis and steatosis in the phytosomal curcumin receiving group compared with the placebo group (p < 0.05). Phytosomal curcumin also significantly reduced waist circumference and blood pressure compared with the placebo group (p < 0.05). There was no significant difference between the phytosomal curcumin and the placebo groups regarding changes in weight, body mass index, fasting blood glucose, liver enzymes, and lipid profile. Conclusion: Curcumin, at a dose of 250 mg per day, might be effective in treating patients with NAFLD. Further studies are necessary to confirm these findings and to discover the underlying mechanisms. Clinical trial registration: https://www.irct.ir/trial/43730, identifier: IRCT20121216011763N39. Copyright © 2023 Safari, Bagherniya, Khoram, Ebrahimi Varzaneh, Heidari, Sahebkar and Askari.
Experts (# of related papers)
Other Related Docs
10. A Systematic Review on the Clinical Significance of Nutraceuticals for Weight Loss, Australian Journal of Herbal and Naturopathic Medicine (2023)
17. Turmeric (Curcuma Longa L.) Usage in the Middle East a Comprehensive Review, Ancient and Traditional Foods, Plants, Herbs and Spices used in the Middle East (2023)
22. Effects of Curcumin on Blood Pressure: A Systematic Review and Dose-Response Meta-Analysis, Nutrition, Metabolism and Cardiovascular Diseases (2023)
43. Inhibitory Effects of Curcumin on Aldose Reductase and Cyclooxygenase-2 Enzymes, Journal of Biomolecular Structure and Dynamics (2021)